LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Search

Ascendis Pharma A-S ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

211.74 2.46

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

210.85

Max

212.84

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-22M

-61M

Pardavimai

56M

214M

Pelno marža

-28.549

Darbuotojai

1,017

EBITDA

-56M

-53M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+23.78% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

927M

13B

Ankstesnė atidarymo kaina

209.28

Ankstesnė uždarymo kaina

211.74

Naujienos nuotaikos

By Acuity

50%

50%

152 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-24 21:41; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

2025-12-24 14:57; UTC

Įsigijimai, susijungimai, perėmimai

Accenture to Acquire Cabel Industry from Fibonacci Group

2025-12-25 23:42; UTC

Rinkos pokalbiai

Nikkei May Trade in Range; Yen in Focus -- Market Talk

2025-12-25 23:40; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

2025-12-25 00:20; UTC

Įsigijimai, susijungimai, perėmimai

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

2025-12-24 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

2025-12-24 21:26; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

2025-12-24 19:35; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-24 19:35; UTC

Rinkos pokalbiai

Treasury Yields Decline Ahead of Christmas -- Market Talk

2025-12-24 19:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2025-12-24 19:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

2025-12-24 19:06; UTC

Rinkos pokalbiai

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

2025-12-24 19:03; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

2025-12-24 17:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-12-24 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-24 17:08; UTC

Įsigijimai, susijungimai, perėmimai

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

2025-12-24 16:53; UTC

Įsigijimai, susijungimai, perėmimai

Nike Climb Boosts Dow, S&P 500 -- WSJ

2025-12-24 16:31; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

2025-12-24 16:28; UTC

Įsigijimai, susijungimai, perėmimai

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

2025-12-24 16:17; UTC

Rinkos pokalbiai

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

2025-12-24 15:33; UTC

Įsigijimai, susijungimai, perėmimai

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

2025-12-24 15:30; UTC

Įsigijimai, susijungimai, perėmimai

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

2025-12-24 15:19; UTC

Įsigijimai, susijungimai, perėmimai

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

2025-12-24 14:49; UTC

Įsigijimai, susijungimai, perėmimai

Mexico's Ollamani Sells Stake in Azteca Stadium

2025-12-24 14:19; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

2025-12-24 14:08; UTC

Įsigijimai, susijungimai, perėmimai

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

2025-12-24 14:06; UTC

Rinkos pokalbiai

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

2025-12-24 13:24; UTC

Rinkos pokalbiai

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

2025-12-24 12:59; UTC

Įsigijimai, susijungimai, perėmimai

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

2025-12-24 12:51; UTC

Įsigijimai, susijungimai, perėmimai

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Ascendis Pharma A-S ADR Prognozė

Kainos tikslas

By TipRanks

23.78% į viršų

12 mėnesių prognozė

Vidutinis 263.42 USD  23.78%

Aukščiausias 325 USD

Žemiausias 220 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ascendis Pharma A-S ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

13

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

157.66 / 167.29Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

152 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat